Clinical and genetic features of rhabdoid tumors of the heart registered with the European Rhabdoid Registry (EU-RHAB)
Language English Country United States Media print-electronic
Document type Case Reports, Journal Article, Research Support, Non-U.S. Gov't
PubMed
24972932
DOI
10.1016/j.cancergen.2014.04.005
PII: S2210-7762(14)00082-9
Knihovny.cz E-resources
- Keywords
- EU-RHAB, Rhabdoid tumor, SMARCB1, heart, intensive multimodal therapy,
- MeSH
- Chromosomal Proteins, Non-Histone biosynthesis genetics MeSH
- DNA-Binding Proteins biosynthesis genetics MeSH
- SMARCB1 Protein MeSH
- Infant MeSH
- Combined Modality Therapy MeSH
- Humans MeSH
- Neoplasm Metastasis MeSH
- Mutation MeSH
- Tumor Suppressor Proteins genetics MeSH
- Heart Neoplasms genetics pathology therapy MeSH
- Antineoplastic Agents therapeutic use MeSH
- Registries MeSH
- Rhabdoid Tumor genetics pathology therapy MeSH
- Transcription Factors biosynthesis genetics MeSH
- Peripheral Blood Stem Cell Transplantation * MeSH
- Check Tag
- Infant MeSH
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Chromosomal Proteins, Non-Histone MeSH
- DNA-Binding Proteins MeSH
- SMARCB1 Protein MeSH
- Tumor Suppressor Proteins MeSH
- Antineoplastic Agents MeSH
- SMARCB1 protein, human MeSH Browser
- SWI-SNF-B chromatin-remodeling complex MeSH Browser
- Transcription Factors MeSH
Rhabdoid tumors are rare but highly aggressive malignancies of infancy and early childhood with a generally unfavorable prognosis. Despite a wide variety of anatomic locations rhabdoid tumors share mutational inactivation of the SWI/SNF (SWItch/Sucrose NonFermentable) core component gene SMARCB1 (also known as INI1, hSNF5 or BAF47) in chromosome 22. As this inactivation usually results in loss of SMARCB1 expression, detectable by an antibody against the SMARCB1 protein, the accurate diagnosis of a rhabdoid tumor may be more distinctly and frequently made. Several reports on rhabdoid tumors presenting in various anatomic sites outside the kidneys and CNS are on record. We report two cases of rhabdoid tumors originating in the heart (cardiac tissue), which were entered into the European Rhabdoid Registry (EU-RHAB). The first case presented with intracardial and -cranial lesions as well as malignant ascites, while the second patient demonstrated an isolated cardiac tumor. This induced a different therapeutic approach and subsequently different clinical course (death 7 weeks after diagnosis in patient 1). Patient 2 presented with a bifocal intracardial tumor without metastases and remains in complete remission for 46 months since diagnosis following multimodal therapy. The second case demonstrates that even in a potentially futile clinical situation early and accurate diagnosis followed by prompt and intensive multimodal therapy may offer prolonged survival, potential cure and improved quality of life.
Children's Hospital Augsburg Swabian Children's Cancer Center Augsburg Germany
Department of Radiology University of the Saarland Homburg Saar Germany
Kardiocentrum and Cardiovascular Research Centre University Hospital Motol Prague Czech Republic
Kiel Pediatric Tumor Registry Department of Pediatric Pathology University Kiel Germany
References provided by Crossref.org